ifebemtinib (IN10018) / InxMed 
Welcome,         Profile    Billing    Logout  
 1 Disease   12 Trials   12 Trials   86 News 


12»
  • ||||||||||  ifebemtinib (IN10018) / InxMed, Trodelvy (sacituzumab govitecan-hziy) / Gilead, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
    Journal:  Targeting FAK improves the tumor uptake of antibody-drug conjugates to strengthen the anti-cancer responses. (Pubmed Central) -  Mar 5, 2025   
    Combination therapy with IN10018 and ADCs targeting either HER2 or TROP2 consistently yielded superior antitumor outcomes compared to monotherapies in animal models. These findings provide compelling preclinical evidence supporting the clinical evaluation of IN10018 in combination with ADCs.
  • ||||||||||  garsorasib (D-1553) / InventisBio
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors (clinicaltrials.gov) -  Oct 15, 2024   
    P1/2,  N=92, Recruiting, 
    These findings provide compelling preclinical evidence supporting the clinical evaluation of IN10018 in combination with ADCs. Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
  • ||||||||||  ifebemtinib (IN10018) / InxMed
    Journal:  A novel FAK-degrading PROTAC molecule exhibited both anti-tumor activities and efficient MDR reversal effects. (Pubmed Central) -  Sep 24, 2024   
    In this study we employed the PROTAC technology, and designed a novel PROTAC molecule F2 targeting FAK based on the FAK inhibitor IN10018...Furthermore, we found that F2 could reduce the protein level of P-gp in HCT8/T cells, thereby contributing to reverse drug resistance from another perspective. Our results will boost confidence in future research focusing on targeting FAK and encourage further investigation of PROTAC with potent in vivo effects.
  • ||||||||||  ifebemtinib (IN10018) / InxMed, Trodelvy (sacituzumab govitecan-hziy) / Gilead, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
    Targeting FAK improves the tumor penetration of antibody-drug conjugates to strengthen the anti-cancer responses (Section 27) -  Mar 5, 2024 - Abstract #AACR2024AACR_6794;    
    The combination regimen comprising IN10018 and the ADCs targeting either HER2 or TROP2 outperformed each monotherapy with respect to antitumor outcomes in different animal experiments. The preclinical evidence for the dual regimen of IN10018 and ADCs warrants a further validation in clinical settings.
  • ||||||||||  Review, Journal:  Roles and inhibitors of FAK in cancer: current advances and future directions. (Pubmed Central) -  Feb 27, 2024   
    This review aims to clarify FAK's role in cancer, offering a comprehensive overview of the current status and future prospects of FAK-targeted therapy and combination approaches. The goal is to provide valuable insights for advancing anti-cancer treatment strategies.
  • ||||||||||  ifebemtinib (IN10018) / InxMed
    Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases:  IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma (clinicaltrials.gov) -  Jan 11, 2024   
    P1,  N=120, Recruiting, 
    Enrolling by invitation --> Recruiting Trial completion date: Jun 2024 --> Sep 2024 | Trial primary completion date: Dec 2023 --> Jun 2024
  • ||||||||||  ifebemtinib (IN10018) / InxMed
    Enrollment open, Combination therapy:  IN10018 Combination Therapy in Treatment-na (clinicaltrials.gov) -  Nov 21, 2023   
    P1/2,  N=120, Recruiting, 
    Trial completion date: Jun 2024 --> Sep 2024 | Trial primary completion date: Dec 2023 --> Jun 2024 Not yet recruiting --> Recruiting
  • ||||||||||  ifebemtinib (IN10018) / InxMed
    New P1/2 trial, Combination therapy:  IN10018 Combination Therapy in Treatment-na (clinicaltrials.gov) -  Sep 8, 2023   
    P1/2,  N=120, Not yet recruiting, 
  • ||||||||||  ifebemtinib (IN10018) / InxMed
    ADC: To Reach The Unreachable () -  Aug 9, 2023 - Abstract #ADCUSA2023ADC_USA_58;    
    Not yet recruiting --> Recruiting While ADC therapies are revolutionizing cancer treatment, high-stroma tumors remain highly challenging due to poor penetration of ADC across the fibrotic barrier of tumor tissues; Focal adhesion kinase is highly expressed in fibrotic stroma, FAK inhibitor IN10018 is able to break fibrotic barrier, consequently enhancing tissue penetration of ADC; IN10018 demonstrated significant synergy in vivo with multiple ADC molecules, especially in high stroma tumor PDX models
  • ||||||||||  IN10018 / InxMed
    Synergism of FAK and ROS1 inhibitors in the treatment of CDH1-deficient cancers mediated by FAK-YAP-TRX signaling (Section 2; Poster Board #7) -  Mar 14, 2023 - Abstract #AACR2023AACR_8804;    
    Here, we evaluated the effects and mechanisms of combined treatment with FAK inhibitor IN10018 and ROS1 inhibitors...This mechanism of action was confirmed by inhibiting the activity of FAK-YAP-TRX downstream signaling molecules and by pretreatment with oxidative stress scavengers. These findings support the co-administration of FAK and ROS1 inhibitors as a therapeutic strategy in CDH1-deficient triple negative breast cancer and diffuse gastric cancer patients and support further clinical testing of this combination regimen.
  • ||||||||||  ifebemtinib (IN10018) / InxMed
    Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases:  IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma (clinicaltrials.gov) -  Nov 22, 2022   
    P1,  N=120, Recruiting, 
    These findings support the co-administration of FAK and ROS1 inhibitors as a therapeutic strategy in CDH1-deficient triple negative breast cancer and diffuse gastric cancer patients and support further clinical testing of this combination regimen. N=52 --> 120 | Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
  • ||||||||||  ifebemtinib (IN10018) / InxMed
    Trial primary completion date, Combination therapy, Monotherapy, Metastases:  IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma (clinicaltrials.gov) -  Nov 16, 2022   
    P1,  N=33, Completed, 
    N=52 --> 120 | Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Dec 2022 --> Dec 2023 Trial primary completion date: Mar 2022 --> Dec 2021
  • ||||||||||  ifebemtinib (IN10018) / InxMed
    Trial completion, Trial completion date, Combination therapy, Monotherapy, Metastases:  IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma (clinicaltrials.gov) -  Sep 15, 2022   
    P1,  N=33, Completed, 
    Trial primary completion date: Mar 2022 --> Dec 2021 Active, not recruiting --> Completed | Trial completion date: Aug 2022 --> Mar 2022
  • ||||||||||  garsorasib (D-1553) / InventisBio
    Trial initiation date, Combination therapy, Metastases:  Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors (clinicaltrials.gov) -  Aug 8, 2022   
    P1/2,  N=92, Not yet recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Aug 2022 --> Mar 2022 Initiation date: Jun 2022 --> Sep 2022
  • ||||||||||  ifebemtinib (IN10018) / InxMed
    Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases:  IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma (clinicaltrials.gov) -  Mar 31, 2022   
    P1,  N=52, Recruiting, 
    This combination warrants further confirmation in a randomized controlled trial. Trial completion date: Dec 2022 --> Jun 2023 | Trial primary completion date: Dec 2021 --> Dec 2022
  • ||||||||||  IN10018 / InxMed
    Journal:  Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK-YAP Signaling. (Pubmed Central) -  Jan 26, 2022   
    Here, it is demonstrated that KRAS G12C inhibition induces sustained activation of focal adhesive kinase (FAK) and show that a combination therapy comprising KRAS G12C inhibition and a FAK inhibitor (IN10018) achieves synergistic anticancer effects...Mechanistically, it is found that both aberrant FAK-YAP signaling and FAK-related fibrogenesis impact on the development of KRAS G12C inhibitor resistance. This study thus illustrates the mechanism of resistance of cancer to the treatment of KRAS G12C inhibitor, as well as an innovative combination therapy to improve treatment outcomes for KRAS G12C mutant cancers.
  • ||||||||||  IN10018 / InxMed
    Journal:  Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells. (Pubmed Central) -  Dec 16, 2021   
    In this study we showed that IN10018, a small molecular FAKi, enhanced antitumor response to RT...FAKi in combination with radiation inhibited the infiltration of granulocytes but enhanced the infiltration of macrophages and T regs in comparison with the radiation or FAKi treatment alone (P < 0.01). These results support the clinical development of FAKi as a radiosensitizer for PDAC and combining FAKi with RT to prime the tumor microenvironment of PDAC for immunotherapy.
  • ||||||||||  Review, Journal:  Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy. (Pubmed Central) -  Sep 25, 2021   
    In addition, FAK degraders have been successfully developed through "proteolysis targeting chimera" (PROTAC) technology, opening up a new way for FAK-targeted therapy. In this paper, the structure and biological function of FAK are reviewed, and we summarize the design, chemical types, and activity of FAK inhibitors according to the development of FAK drugs, which provided the reference for the discovery of new anticancer agents.
  • ||||||||||  ifebemtinib (IN10018) / InxMed
    Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases:  IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma (clinicaltrials.gov) -  Aug 18, 2021   
    P1,  N=52, Recruiting, 
    In this paper, the structure and biological function of FAK are reviewed, and we summarize the design, chemical types, and activity of FAK inhibitors according to the development of FAK drugs, which provided the reference for the discovery of new anticancer agents. Trial completion date: Sep 2022 --> Dec 2022 | Trial primary completion date: Sep 2021 --> Dec 2021
  • ||||||||||  ifebemtinib (IN10018) / InxMed
    Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases:  IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma (clinicaltrials.gov) -  Mar 21, 2021   
    P1,  N=52, Recruiting, 
    Trial completion date: Sep 2022 --> Dec 2022 | Trial primary completion date: Sep 2021 --> Dec 2021 Trial completion date: Mar 2021 --> Sep 2022 | Trial primary completion date: Mar 2021 --> Sep 2021
  • ||||||||||  ifebemtinib (IN10018) / InxMed
    Enrollment open, Trial initiation date, Combination therapy, Monotherapy, Metastases:  IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma (clinicaltrials.gov) -  Mar 18, 2020   
    P1,  N=52, Recruiting, 
    Our results indicate that KRAS G12C cancer patients can be better treated by the combination of IN10018 with KRAS G12C inhibitor. Not yet recruiting --> Recruiting | Initiation date: Dec 2019 --> Mar 2020